Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Since then, we have seen tavapadon deliver positive phase 3 results in Parkinson's disease patients, and while I am not too ...

Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...

Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

along with royalties on product sales. AbbVie said EvolveImmune is developing next-generation biotherapeutics to overcome the challenges of cancer-cell resistance to current immunotherapies.

One was to be a diversified medical products company – Abbott – and the other, a new researched-based global biopharmaceutical company – AbbVie. In January 2013, AbbVie was formed.

When evaluating AbbVie alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise: AbbVie holds a middle position in terms of the debt-to-equity ratio compared to ...